William Wu, Chihoon Ahn, Jennifer Scull, Kevin E Fisher, Angshumoy Roy, Dolores H Lopez-Terrada, Andrea N Marcogliese, Anindita Ghosh
{"title":"ETV6::RUNX1和P2RY8::CRLF2融合在复发性急性B淋巴细胞白血病患者中的共存","authors":"William Wu, Chihoon Ahn, Jennifer Scull, Kevin E Fisher, Angshumoy Roy, Dolores H Lopez-Terrada, Andrea N Marcogliese, Anindita Ghosh","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>B-cell acute lymphoblastic leukemias (B-ALLs) harbor recurrent chromosomal aberrations associated with prognostic and therapeutic significance. Although these major driver genetic abnormalities are generally mutually exclusive, they are rarely reported to co-occur. Here, we present the case of a child with B-ALL who suffered two relapses with short event-free intervals. The patient was found to have co-existence of translocation t(12;21) causing <i>ETV6::RUNX1</i> fusion and an interstitial deletion of chromosome X leading to <i>P2RY8::CRLF2</i> fusion. While ETV6::RUNX1 was readily detected by cytogenetic analysis of the bone marrow at the time of diagnosis, the concurrent <i>P2RY8::CRLF2</i> fusion was discovered upon molecular genetic analysis at second relapse. Notably, <i>ETV6::RUNX1</i> and <i>P2RY8::CRLF2</i> each hallmark molecular subclasses of B-ALL with distinct mutational landscapes and clinical prognoses. It is not yet known how co-existing leukemogenic chromosomal aberrations interact to modify treatment response and relapse risk of B-ALL. This case highlights the possibility that co-existing molecular aberrations may greatly impact the clinical course of B-ALL but may be under-recognized in the initial workup using standard diagnostic algorithms.</p>","PeriodicalId":8228,"journal":{"name":"Annals of clinical and laboratory science","volume":"55 1","pages":"133-141"},"PeriodicalIF":1.1000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Co-Occurrence of <i>ETV6::RUNX1</i> and <i>P2RY8::CRLF2</i> Fusion in a Patient with Relapsed Acute B Lymphoblastic Leukemia.\",\"authors\":\"William Wu, Chihoon Ahn, Jennifer Scull, Kevin E Fisher, Angshumoy Roy, Dolores H Lopez-Terrada, Andrea N Marcogliese, Anindita Ghosh\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>B-cell acute lymphoblastic leukemias (B-ALLs) harbor recurrent chromosomal aberrations associated with prognostic and therapeutic significance. Although these major driver genetic abnormalities are generally mutually exclusive, they are rarely reported to co-occur. Here, we present the case of a child with B-ALL who suffered two relapses with short event-free intervals. The patient was found to have co-existence of translocation t(12;21) causing <i>ETV6::RUNX1</i> fusion and an interstitial deletion of chromosome X leading to <i>P2RY8::CRLF2</i> fusion. While ETV6::RUNX1 was readily detected by cytogenetic analysis of the bone marrow at the time of diagnosis, the concurrent <i>P2RY8::CRLF2</i> fusion was discovered upon molecular genetic analysis at second relapse. Notably, <i>ETV6::RUNX1</i> and <i>P2RY8::CRLF2</i> each hallmark molecular subclasses of B-ALL with distinct mutational landscapes and clinical prognoses. It is not yet known how co-existing leukemogenic chromosomal aberrations interact to modify treatment response and relapse risk of B-ALL. This case highlights the possibility that co-existing molecular aberrations may greatly impact the clinical course of B-ALL but may be under-recognized in the initial workup using standard diagnostic algorithms.</p>\",\"PeriodicalId\":8228,\"journal\":{\"name\":\"Annals of clinical and laboratory science\",\"volume\":\"55 1\",\"pages\":\"133-141\"},\"PeriodicalIF\":1.1000,\"publicationDate\":\"2025-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annals of clinical and laboratory science\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"MEDICAL LABORATORY TECHNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of clinical and laboratory science","FirstCategoryId":"3","ListUrlMain":"","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}
Co-Occurrence of ETV6::RUNX1 and P2RY8::CRLF2 Fusion in a Patient with Relapsed Acute B Lymphoblastic Leukemia.
B-cell acute lymphoblastic leukemias (B-ALLs) harbor recurrent chromosomal aberrations associated with prognostic and therapeutic significance. Although these major driver genetic abnormalities are generally mutually exclusive, they are rarely reported to co-occur. Here, we present the case of a child with B-ALL who suffered two relapses with short event-free intervals. The patient was found to have co-existence of translocation t(12;21) causing ETV6::RUNX1 fusion and an interstitial deletion of chromosome X leading to P2RY8::CRLF2 fusion. While ETV6::RUNX1 was readily detected by cytogenetic analysis of the bone marrow at the time of diagnosis, the concurrent P2RY8::CRLF2 fusion was discovered upon molecular genetic analysis at second relapse. Notably, ETV6::RUNX1 and P2RY8::CRLF2 each hallmark molecular subclasses of B-ALL with distinct mutational landscapes and clinical prognoses. It is not yet known how co-existing leukemogenic chromosomal aberrations interact to modify treatment response and relapse risk of B-ALL. This case highlights the possibility that co-existing molecular aberrations may greatly impact the clinical course of B-ALL but may be under-recognized in the initial workup using standard diagnostic algorithms.
期刊介绍:
The Annals of Clinical & Laboratory Science
welcomes manuscripts that report research in clinical
science, including pathology, clinical chemistry,
biotechnology, molecular biology, cytogenetics,
microbiology, immunology, hematology, transfusion
medicine, organ and tissue transplantation, therapeutics, toxicology, and clinical informatics.